188 related articles for article (PubMed ID: 31704978)
1. Rotigotine suppresses sleep-related muscle activity augmented by injection of dialysis patients' sera in a mouse model of restless legs syndrome.
Muramatsu K; Chikahisa S; Shimizu N; Séi H; Inoue Y
Sci Rep; 2019 Nov; 9(1):16344. PubMed ID: 31704978
[TBL] [Abstract][Full Text] [Related]
2. Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial.
Dauvilliers Y; Benes H; Partinen M; Rauta V; Rifkin D; Dohin E; Goldammer N; Schollmayer E; Schröder H; Winkelman JW
Am J Kidney Dis; 2016 Sep; 68(3):434-43. PubMed ID: 26851201
[TBL] [Abstract][Full Text] [Related]
3. Effects of rotigotine on clinical symptoms, quality of life and sleep hygiene adequacy in haemodialysis-associated restless legs syndrome.
Esteve V; Carneiro J; Salazar G; Pou M; Tapia I; Fulquet M; Duarte V; Saurina A; Moreno F; Ramírez de Arellano M
Nefrologia (Engl Ed); 2018; 38(1):79-86. PubMed ID: 29198453
[TBL] [Abstract][Full Text] [Related]
4. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
Bogan RK
Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
[TBL] [Abstract][Full Text] [Related]
5. Motor restlessness, sleep disturbances, thermal sensory alterations and elevated serum iron levels in Btbd9 mutant mice.
DeAndrade MP; Johnson RL; Unger EL; Zhang L; van Groen T; Gamble KL; Li Y
Hum Mol Genet; 2012 Sep; 21(18):3984-92. PubMed ID: 22678064
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome.
Ferini-Strambi L; Marelli S; Galbiati A
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):967-75. PubMed ID: 27224246
[TBL] [Abstract][Full Text] [Related]
7. Rotigotine for restless legs syndrome.
Davies S
Drugs Today (Barc); 2009 Sep; 45(9):663-8. PubMed ID: 19956807
[TBL] [Abstract][Full Text] [Related]
8. BTBD9 and dopaminergic dysfunction in the pathogenesis of restless legs syndrome.
Lyu S; Doroodchi A; Xing H; Sheng Y; DeAndrade MP; Yang Y; Johnson TL; Clemens S; Yokoi F; Miller MA; Xiao R; Li Y
Brain Struct Funct; 2020 Jul; 225(6):1743-1760. PubMed ID: 32468214
[TBL] [Abstract][Full Text] [Related]
9. Restless legs syndrome in patients on hemodialysis: Polysomnography findings.
Bambini BBM; Moysés RMA; Batista LCD; Coelho BBSS; Tufik S; Elias RM; Coelho FM
Hemodial Int; 2019 Oct; 23(4):445-448. PubMed ID: 31579966
[TBL] [Abstract][Full Text] [Related]
10. Dopamine agonists in restless leg syndrome treatment and their effects on sleep parameters: A systematic review and meta-analysis.
Yeh WC; Li YS; Chang YP; Hsu CY
Sleep Med; 2024 Jul; 119():379-388. PubMed ID: 38761607
[TBL] [Abstract][Full Text] [Related]
11. MEIS1 and BTBD9: genetic association with restless leg syndrome in end stage renal disease.
Schormair B; Plag J; Kaffe M; Gross N; Czamara D; Samtleben W; Lichtner P; Ströhle A; Stefanidis I; Vainas A; Dardiotis E; Sakkas GK; Gieger C; Müller-Myhsok B; Meitinger T; Heemann U; Hadjigeorgiou GM; Oexle K; Winkelmann J
J Med Genet; 2011 Jul; 48(7):462-6. PubMed ID: 21572129
[TBL] [Abstract][Full Text] [Related]
12. A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.
Winkelman JW; Mackie SE; Mei LA; Platt S; Schoerning L
Sleep Med; 2016 Aug; 24():18-23. PubMed ID: 27810181
[TBL] [Abstract][Full Text] [Related]
13. Post Hoc Analysis of Data from Two Clinical Trials Evaluating the Minimal Clinically Important Change in International Restless Legs Syndrome Sum Score in Patients with Restless Legs Syndrome (Willis-Ekbom Disease).
Ondo WG; Grieger F; Moran K; Kohnen R; Roth T
J Clin Sleep Med; 2016 Jan; 12(1):63-70. PubMed ID: 26446245
[TBL] [Abstract][Full Text] [Related]
14. Daytime symptoms of restless legs syndrome--clinical characteristics and rotigotine effectiveness.
Takahashi M; Ikeda J; Tomida T; Hirata K; Hattori N; Inoue Y
Sleep Med; 2015 Jul; 16(7):871-6. PubMed ID: 26002761
[TBL] [Abstract][Full Text] [Related]
15. Rotigotine transdermal delivery for the treatment of restless legs syndrome.
Sixel-Döring F; Trenkwalder C
Expert Opin Pharmacother; 2010 Mar; 11(4):649-56. PubMed ID: 20163275
[TBL] [Abstract][Full Text] [Related]
16. Clinical management of restless legs syndrome in end-stage renal disease patients.
Sahli ZT; Jo J; Mousa SA; Tarazi FI
CNS Spectr; 2017 Feb; 22(1):14-21. PubMed ID: 27702420
[TBL] [Abstract][Full Text] [Related]
17. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study.
Stiasny-Kolster K; Kohnen R; Schollmayer E; Möller JC; Oertel WH;
Mov Disord; 2004 Dec; 19(12):1432-8. PubMed ID: 15390055
[TBL] [Abstract][Full Text] [Related]
18. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study.
Trenkwalder C; Canelo M; Lang M; Schroeder H; Kelling D; Berkels R; Schollmayer E; Heidbrede T; Benes H
Sleep Med; 2017 Feb; 30():257-265. PubMed ID: 26896370
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis-Ekbom disease).
Elshoff JP; Hudson J; Picchietti DL; Ridel K; Walters AS; Doggett K; Moran K; Oortgiesen M; Ramirez F; Schollmayer E
Sleep Med; 2017 Apr; 32():48-55. PubMed ID: 28366342
[TBL] [Abstract][Full Text] [Related]
20. Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study.
Garcia-Borreguero D; Allen R; Hudson J; Dohin E; Grieger F; Moran K; Schollmayer E; Smit R; Winkelman J
Curr Med Res Opin; 2016; 32(1):77-85. PubMed ID: 26569149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
